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Abstract 
INTRODUCTION: Volumes of hippocampus and cholinergic basal forebrain are associated 
with delayed recall performance and may modulate the effect of a muscarinic receptor 
antagonist on delayed recall in healthy volunteers.  
METHODS: We studied 15 older adults before and after oral administration of a single dose 
of 1mg or 2mg of the preferential M1 muscarinic receptor antagonist trihexyphenidyl 
(Artane™) or placebo in a double-blind randomized cross-over design. Hippocampus and 
basal forebrain volumes were measured using MRI. 
RESULTS: We found a significant interaction between treatment and hippocampus volume 
and a trend level effect between treatment and anterior basal forebrain volume on task 
performance, with an attenuation of the association between volume size and performance 
with trihexyphenidyl.  
DISCUSSION: These findings suggest a reduction of delayed recall performance with 
increasing doses of the muscarinic antagonist that is related to an uncoupling of the 
association of task performance with cholinergic basal forebrain and hippocampus volumes. 
 Introduction 
Administration of trihexyphenidyl hydrochloride (Artane™) and other muscarinic 
receptor antagonists has been reported to decrease delayed recall in healthy volunteers [1-
3]. These findings are consistent with cholinergic transmission playing a key role in attention 
and memory tasks that require effort and concentration [4]. The main cholinergic input to the 
human cerebral cortex arises from the basal forebrain cholinergic nuclei [5]. The 
hippocampus is involved in the coherent representation of a memory, a requirement for 
successful retrieval [6]. The main cholinergic input to the hippocampus arises from the most 
anterior subnuclei of the cholinergic basal forebrain [7], termed Ch1 and Ch2 according to 
Mesulam’s nomenclature [8]. 
In the present study, we examined whether the volumes of the anterior basal 
forebrain and hippocampus, as measured from structural MRI scans, modulate the effect of 
anticholinergic treatment with trihexyphenidyl on delayed recall performance in a group of 15 
cognitively and physically healthy older adults. We expected that a higher volume would be 
associated with higher delayed recall performance and that this association would be 
reduced with higher doses of trihexyphenidyl.
 Participants and Methods 
The study included 15 healthy elderly individuals (8 women), mean age was 66.9 (SD 
3.7) years, ranging between 62 and 74 years, and mean education was 16.7 (SD 2.3) years. 
Individuals did not take medications known to affect cognitive functioning, such as 
neuroleptics or antidepressants, at least 2 weeks before beginning the study and had a 
negative urine toxicology screen. Further details of recruitment have been described before 
[9]. All subjects were only examined if they gave their written informed consent. The study 
has been carried out in accordance with The Code of Ethics of the World Medical 
Association (Declaration of Helsinki). 
 
Neuropsychological testing and Study Design 
Participants were recruited as part of a study on the effects of APOE variants on the 
response to trihexyphenidyl [9]. Delayed recall (after 15 minutes) was tested using the 
Buschke Selective Reminding Test [10], administered before as well as 1, 2.5 and 5 hours 
after drug/placebo administration. Each subject participated in the 3-week, double-blind, 
randomized, placebo-controlled study, with sessions taking place one week apart: treatment 
conditions were placebo, 1.0mg and 2.0mg of trihexyphenidyl. To exclude training effects 
within and across treatment sessions, twelve parallel word lists were used, in a randomized 
rotational basis across sessions. The same list was used across subjects in each of the 12 
assessment periods (treatment (3) X test time (4)). 
 
MRI data acquisition and analysis 
The acquisition was performed on a 1.5 T Siemens Vision system (Erlangen, 
Germany) at the Nathan S. Kline Institute for Psychiatric Research, NY, USA. Images were 
acquired using a sagittal magnetization prepared rapid gradient-echo sequence [MPRAGE; 
repetition time (TR)/echo time (TE)=11.4/11.9 ms, 1 excitation (NEX), matrix=256 x 256, 
FOV=307 mm, 1.2mm3 isotropic voxel, 172 slices, no gap].  
MRI data processing followed procedures described previously for hippocampus 
[11] and basal forebrain [12] volumetry, implemented in SPM8 and the VBM8-toolbox in 
Matlab. Basal forebrain subregions [8] were determined according to a map from an in cranio 
post mortem MRI scan and histology of a single individual’s brain, as previously described 
[12]. The total intracranial volume (TIV) was used in the statistical model to account for 
differences in head size, and was calculated as the sum of the total segmented gray matter, 
white matter and cerebrospinal fluid volumes in native space. We selected volumes of left 
and right hippocampus as well as of most anterior basal forebrain nuclei, Ch1 and Ch2 
according to Mesulam’s nomenclature [8], that provide the main cholinergic innervation of the 
hippocampus [7]. 
 
Statistical analysis 
We determined the effect of treatment on delayed recall across subjects using a 
mixed effects model with subject-related random effects, controlling for age and sex. For time 
after drug intake (0 to 5 hours), we compared a linear with a second order polynomial term. 
The model fit was compared between the two nested models (first vs. second order 
polynomial term for time) using Akaike’s information criterion (AIC) [13]. 
To test for an interaction between volumes of basal forebrain and hippocampus, 
respectively, and the drug effect, we selected performance at the time of peak drug effect (1 
to 2.5 hours post ingestion [14]); we also tested for main effects of volume and drug, and 
controlled for total intracranial volume, sex and age in all analyses. Significance of 
parameters was determined using t-statistics with degrees of freedom determined according 
to the Satterthwaite approximation. 
Analyses were performed with R, version 3.1.1, including the libraries “lme4” and 
“lmerTest”, available at http://cran.r-project.org/web/packages.   
Results 
In the basic model across all time points, we found a significant linear effect of time 
on delayed recall performance (t=-4.6, df=162, p<0.001). There was no significant main 
effect of treatment (t=-1.68, df=162, p=0.09). The second order polynomial model improved 
the fit over the linear model (AIC=837.7 for the linear model, and AIC=813.1 for the 
polynomial model). 
For hippocampus, considering the peak drug effect time points only, we detected a 
significant volume by treatment interaction (left and right hippocampus: t=-2.1, df=72, p=0.04; 
Figure 1) as well as a significant main effect of treatment (t=-3.2, df=72, p=0.002). With 
anterior basal forebrain volume, we observed a trend level significant interaction effect (t=-
1.8, df=72, p=0.074; Figure 2), and a significant main effect of treatment (t=-3.2, df=72, 
p=0.002). AIC of nested models indicated moderately improved fit for the complex models 
compared with the basic model: basic model AIC = 423.4; full model with Ch1/2, AIC = 
421.3; full model with left hippocampus, AIC = 422.3; full model with right hippocampus, AIC 
= 422.2. 
- Figures 1 and 2 near here - 
 Discussion 
We found a decline in delayed recall performance in response to the muscarinic 
antagonist trihexyphenidyl, consistent with previous studies [1-3] and predictions. We used a 
mixed effects model to take blocking of observations within subjects and inter-individual 
variation in performance levels into account [15]. The time activity curve of the drug was best 
modeled by a second order polynomial consistent with the previously reported central 
pharmacodynamics of trihexyphenidyl [14]. Under placebo, hippocampal and anterior basal 
forebrain volumes were positively associated with delayed recall performance. The 
treatment-induced decline of performance was associated a reduced or even revers 
association between regional volume and task performance with a higher dose of the 
muscarinic receptor antagonist (Figures 1 and 2). The treatment-induced reductions of 
performance, compared with placebo, were more pronounced at higher volumes. This finding 
suggests the presence of a possible floor effect for performance at smaller volumes whereby 
performance levels only decrease slightly as a consequence of medication since cholinergic 
blocking is less effective when the system and its input areas in the hippocampus are already 
impaired. 
The numerically similar effects for the hippocampus and the cholinergic system would 
indicate that cholinergic input towards the hippocampus from the anterior basal forebrain (the 
main source of cholinergic projections to the hippocampus [7]) only partially regulates 
hippocampus-related determinants of delayed recall performance [16]. Due to the limited 
number of participants in our sample, however, we did not formally test for such a potential 
mediation effect. 
Contrary to our observations, it may be expected that the effect of anticholinergic 
treatment on task performance should be less pronounced with larger volumes rather than 
with smaller volumes, if the former indicate a higher number of neurons with viable M1 
muscarinic receptors that could compensate for a partial block of receptors. This assumption 
would hold if variation in volume size were not linked as a state marker to performance but 
mainly represented a trait marker of reserve capacity, and if the level of anticholinergic effect 
were just above the threshold necessary to elicit functional effects. Here, however, we 
examined a sample of older adults where a low dose of the drug already induced significant 
decline in performance. This suggests that variation in cholinergic system integrity serves at 
least partially as a state marker for functional performance, and at smaller volumes the 
blockade of muscarinic receptors occurs in an already impaired cholinergic system. To better 
resolve this question, one would need to study the interaction between anticholinergic 
treatment, and hippocampus and basal forebrain volumes in healthy young adults where 
variation in volume is expected not to be rate limiting for task performance. 
Increased atrophy of the cholinergic basal forebrain and decline of cholinergic 
functioning over and above the effects of normal aging have been associated with cognitive 
decline and the development of dementia in neurodegenerative conditions such as 
Alzheimer’s disease and Lewy body disorders [17]. Controlled anticholinergic stress tests 
have been proposed as prognostic markers for the development of dementia in the elderly 
[18, 19]. MRI-based measurements of the structural integrity of the cholinergic basal 
forebrain and its functionally relevant target areas may provide important neurobiological 
additional information to such pharmacological stress tests. 
In summary, our findings, which should be replicated in an independent sample, 
suggest that anticholinergic treatment leads to a partial uncoupling of hippocampus and 
basal forebrain atrophy from delayed recall task performance, providing in vivo evidence that 
both structures functionally subserve delayed recall mediated by cholinergic input to the 
hippocampus. 
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 Figure legends: 
Figure 1: Association of delayed recall performance with left hippocampus volume at 
different levels of treatment 
Using the “effects” library in R, we computed the fitted values and standard errors for delayed 
recall under the model for the interaction term of treatment by (mean centered) volume with 
the values of the other predictors being fixed at typical values, i.e. for an interval scaled 
covariate at its mean, and for a factor at its proportional distribution in the data, as described 
in [20].  
Treatment 1mg = 1 mg trihexyphenidyl 
Treatment 2mg = 2mg trihexyphenidyl 
 
Figure 2: Association of delayed recall performance with anterior basal forebrain 
(Ch1/2) volume at different levels of treatment 
For legend see figure 1. 
 Figure 1: Fit of delayed recall performance with left hippocampus volume at different 
levels of treatment 
 
 
 
 
 Figure 2: Fit of delayed recall performance with anterior basal forebrain (Ch1/2) 
volume at different levels of treatment 
 
 
